Updates

  1. Prostate cancer

    Expert emphasises healthy lifestyle in prostate cancer care.
    Industry news

    Read more »
  2. Leukemia

    Kymriah, the first FDA-approved CAR-T cell therapy, is showing promising results in treating children with acute lymphoblastic leukemia.
    leukemia

    Read more »
  3. Thyroid cancer

    The UK institute NICE gives 3 nods in thyroid cancer: Cometriq (cabozantinib), Nexavar (sorafenib) and Lenvima (lenvatinib).
    thyroid cancer

    Read more »
  4. New prices negotiated! Reductions for 38 products

    Price decreases for 38 medicines

    Read more »
  5. Leukemia

    In a recent trial, 80% of patients with (MRD)-positive acute lymphoblastic leukemia (ALL) who were treated with a drug called Blincyto (blinatumomab) achieved a complete response.
    Industry news

    Read more »
  6. Oncology

    Scientists experimenting with an innovative treatment for cancer have now devised a targeted injection that has already successfully eliminated tumours in mice.
    Industry news

    Read more »
  7. Immunotherapy

    The first ever patient to be treated with a new type of CAR-T cell therapy in a novel clinical trial is now in remission.
    Industry news

    Read more »
  8. New microneedle product could help people with ALS, MS and diabetes

    Remember the hypospray from Star Trek? Maybe it's close to reality.

    Star Trek magazine cover

    Read more »
  9. Breast cancer

    A new combination of medicines is showing positive results in ER/HER2-Positive breast cancer.
    Industry news

    Read more »
  10. New medicines coming soon!

    A list of medicines TheSocialMedwork will soon be making available.

    New medicines

    Read more »
  11. Ovarian cancer

    New test detects ovarian and 7 other cancers using simple blood sample.
    Industry news

    Read more »
  12. Breast cancer

    Lynparza (olaparib) is the first PARP inhibitor approved to treat breast cancer, and the first medicine ever for metastatic breast cancer who have a “BRCA” gene mutation.
    Industry news

    Read more »